Accelerate Innate Immunity-Focused IBD Research with Our Anti-CD40 Antibody-Induced Colitis Model

Understanding the complex immunological mechanisms that drive inflammatory bowel disease (IBD) requires robust and translational preclinical models. The Anti-CD40 Antibody-Induced Colitis Model in SCID mice is a well-established platform for investigating innate immune-mediated intestinal inflammation and evaluating the efficacy of novel therapeutic candidates targeting inflammatory pathways.

Model Overview

In this study, colitis was induced in SCID mice through administration of an anti-CD40 antibody, resulting in rapid and reproducible intestinal inflammation driven primarily by innate immune activation. Disease progression and therapeutic responses were evaluated using a comprehensive set of clinical, molecular, and histopathological endpoints, providing valuable insights for preclinical drug development.

Comprehensive Readouts and Analytical Capabilities

The case study highlights a multidimensional evaluation strategy, including:

• Clinical Disease Assessment
  Monitoring of disease progression through Disease Activity Index (DAI) scoring and body weight measurements to evaluate treatment efficacy and overall disease severity.
• Inflammatory Biomarker Analysis
  Quantitative assessment of key inflammatory mediators associated with intestinal inflammation, supporting mechanistic studies and pharmacodynamic evaluations.
• Histopathological Evaluation
  Comprehensive microscopic examination of colon tissues to assess mucosal injury, inflammatory cell infiltration, tissue architecture changes, and overall disease burden.

Why Download This Case Study?

By downloading this case study, you will learn:

• How to establish a reliable Anti-CD40 Antibody-Induced Colitis Model in SCID mice
• Which endpoints are most informative for assessing innate immune-driven intestinal inflammation
• How to evaluate biologics and immunomodulatory therapies in a translational preclinical setting
• How this model can support mechanism-of-action studies and therapeutic development programs

Explore how our Anti-CD40 Antibody-Induced Colitis Model can help generate robust efficacy data and advance the development of next-generation therapies for inflammatory bowel disease.

You might be interested in...